Stem Cell Therapy for Knee Osteoarthritis: Innovative Solutions

Stem Cell Therapy for Knee Osteoarthritis: Wharton’s Jelly Research

Stem cell research plays a key role in advancing regenerative orthopaedic care in Malaysia. Through close collaboration with Universiti Kebangsaan Malaysia (UKM), we focus on translating laboratory science into safe, real-world clinical applications.

In particular, our research explores how stem cells may support joint preservation, pain reduction, and functional recovery.

One of our primary research interests involves Wharton’s Jelly–derived mesenchymal stem cells (WJ-MSCs). These cells come from the umbilical cord and are known for their anti-inflammatory and immunomodulatory properties.

Importantly, WJ-MSCs show strong potential in treating degenerative joint conditions. Therefore, they have become a key focus in regenerative medicine research worldwide.

What Are Wharton’s Jelly Stem Cells?

Wharton’s Jelly is the jelly-like tissue found in the umbilical cord. It contains mesenchymal stem cells (MSCs) with strong healing and anti-inflammatory properties. These cells can:

Reduce inflammation in the joint
Help repair cartilage and support tissue regeneration
Improve the body’s natural healing process

Unlike stem cells from bone marrow or fat, WJ-MSCs are easy to collect and less likely to cause immune reactions. They also have a high ability to turn into cartilage cells.

How WJ-MSC Therapy Works

In this therapy, stem cells are injected directly into the knee joint.

Once injected, the cells can:

Reduce joint inflammation and swelling
Encourage cartilage repair
Support improved joint function and mobility

As a result, patients may notice less pain and better movement over time.

Clinical Research in Knee Osteoarthritis

Under the leadership of Assoc Prof Dato’ Dr Badrul Akmal Hisham, UKM-led clinical studies evaluated the safety and early effectiveness of intra-articular WJ-MSC injections in patients with symptomatic knee osteoarthritis.

Over a six-month follow-up period, patients reported reduced pain and improved knee function. In addition, researchers observed improvements in validated clinical scores such as VAS, KOOS, IKDC, and Lysholm. Notably, no serious adverse events occurred during the study.

As a result, these findings support the safety profile of WJ-MSC therapy when applied in a controlled clinical setting.

In a Phase I clinical trial, the safety and early effectiveness of intra-articular WJ-MSC injections were tested in patients with symptomatic osteoarthritis. Over six months, the study found:

No serious side effects
Reduced pain measured by Visual Analogue Scale (VAS)
Improved function in KOOS, IKDC, and Sit-to-Stand tests

These results demonstrate the anti-inflammatory and regenerative potential of WJ-MSC therapy.

Advantages of Wharton’s Jelly Stem Cells

Minimally invasive: No surgery is needed to collect cells
High healing potential: Can turn into cartilage and other musculoskeletal tissue
Reduces inflammation: Helps the joint recover with less pain
Evidence-based: Clinical trials show safety and functional improvement

Also, this therapy can help patients delay or avoid knee replacement surgery.

Who Can Benefit?

Patients with early to moderate knee osteoarthritis
People seeking joint preservation without surgery
Those looking to improve mobility and reduce pain naturally

In addition, active individuals or athletes with early cartilage damage may benefit.

Looking Ahead

Our ongoing research aims to refine stem cell therapy protocols and explore combination treatments for ACL injuries, cartilage repair, and early osteoarthritis.

We are committed to translating research into clinical practice, ensuring that patients in Kuala Lumpur and Malaysia have access to cutting-edge regenerative therapies.

For more information or to inquire about participation in research trials, contact us:
enquiries@klorthosports.com

Mesenchymal Stem Cells